Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Retained Earnings (2024 - 2025)

Historic Retained Earnings for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to -$1.1 billion.

  • Kura Oncology's Retained Earnings fell 2475.27% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 2475.27%. This contributed to the annual value of -$895.4 million for FY2024, which is N/A changed from last year.
  • Per Kura Oncology's latest filing, its Retained Earnings stood at -$1.1 billion for Q3 2025, which was down 2475.27% from -$1.0 billion recorded in Q2 2025.
  • Kura Oncology's Retained Earnings' 5-year high stood at -$771.0 million during Q1 2024, with a 5-year trough of -$1.1 billion in Q3 2025.